MacroGenics, Inc.
MGNX
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who haveā¦ read more
Healthcare
Biotechnology
12 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.37
Price+0.74%
$0.01
1Y
Price
Market Cap
$86.592m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-150.3%
EBITDA Margin-163.0%
Net Profit Margin-214.5%
Free Cash Flow MarginRevenue
$163.871m
+10.5%
1y CAGR+35.8%
3y CAGR+52.1%
5y CAGREarnings
-$36.399m
+45.7%
1y CAGR-167.1%
3y CAGR-116.0%
5y CAGREPS
-$0.57
+46.7%
1y CAGR-158.1%
3y CAGR-108.9%
5y CAGRBook Value
$46.618m
$245.416m
Assets$198.798m
Liabilities$37.247m
DebtDebt to Assets
15.2%
-1.4x
Debt to EBITDAFree Cash Flow
-$74.576m
-3.5%
1y CAGR+6.0%
3y CAGR+14.4%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company